Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409874 | 1.00 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL29409887 | 1.00 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL26695967 | 0.88 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL30733363 | 0.88 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL12179449 | 0.88 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20555557 | 0.87 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL14801812 | 0.86 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL26695871 | 0.86 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL2559419 | 0.86 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL14801368 | 0.86 | DGAT1 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12479847-B2 | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12398140-B2 | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-115023428-B | Pyrimidopyrroles compounds | 江苏先声药业有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-114315838-B | Pyrimidopyrroles compounds | 江苏先声药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-115244055-B | Pyrimidine five-membered ring derivative and application thereof | 江苏先声药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117425660-A | Aromatic heterocyclic compound, intermediate thereof, pharmaceutical composition and application | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117247387-A | Aromatic heterocyclic compound and preparation method thereof | 上海翊石医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023222005-A1 | AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-11-23 | — | — | WO | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079231-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | GATEKEEPER PHARMACEUTICAL, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079231-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | GATEKEEPER PHARMACEUTICAL, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | DGAT1 3483/4885MAPT 2274/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | DGAT1 623/4885MAPT 3622/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | DGAT1 623/4885MAPT 3622/4885 |
| US-12479847-B2 | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 | LRRK2, PARK7, PINK1 | DGAT1 3523/4885MAPT 178/4885 |
| US-12398140-B2 | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia | DPYD, PTBP1, SARNP | DGAT1 4148/4885MAPT 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.